SecBot SecBot

BVS

Bioventus Inc.
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001665988 Healthcare & Medical Devices
$10.46 −0.20 (−1.88%)
Nov 16 4:00 PM ET · prev $10.66
Market cap
$898.2M
Small cap
Consensus
Buy
89% Buy or better · 9 analysts
Median target
$16.00
+53% · range $15.00–18.00
1 year
+48.2%
from $7.06 · Nov 17
30 days
−22.5%
from $13.49
52-week range
$6.53–15.26
−31% from high · low Nov 20
Avg volume 20D
680.9K
Nov 3 spike 2.45M
Short interest
3.02M
≈3.6% of shares · −4.9%
Days to cover
6.6
at average volume
Insider net
−$105.4K
0 buyers · 1 seller · 12 mo
New fund stakes
1
Q3 2026 13F · 0 exits
Filing reports
17
analyzed by SecBot
SecBot read MIXED 5 reports · 90 days
Balance 0 bearish · 0 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 4/5

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $105.4K.

  • InstitutionsMIXED

    Q3 2026: 22 added (1 new), 15 trimmed or exited.

  • AnalystsBULLISH

    8 of 9 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −4.9% to 3.02M shares. 6.6 days to cover, ≈3.6% of shares.

  • TrendDOWNTREND

    20% below its 50-day average.

Who's buying

13F· Q3 2026
1
new positions
0
exits
FundMoveSharesValue
AMERICAN CENTURY COMPANIES INCADD2,162,426$29.5M
RENAISSANCE TECHNOLOGIES LLCTRIM432,136$5.9M
FMR LLCTRIM336,213$4.6M
FRANKLIN TEMPLETON INCDOUBLED324,984$3.7M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPADD248,904$3.4M
Bank of New York Mellon CorpADD194,991$2.7M
SEI INVESTMENTS CODOUBLED167,280$2.3M
LPL Financial LLCDOUBLED153,078$2.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

9 analysts
Buy 89% rate it Buy or better
Strong Buy2Buy6Hold1Sell0Strong Sell0
12-month targets · 5 analysts

Price is below the lowest target. Median implies +53%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 3, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Aug 17, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Aug 17, 2026Cantor Fitzgerald
REITERATE
REITERATEOverweight
Jun 30, 2026Barrington Research
MAINTAIN
MAINTAINOutperform
Jun 16, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
May 22, 2026Barrington Research
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$105.4K
sold · 1 insider
DateInsiderTypeValue
Jun 3, 2026
NEELS GUIDO J
Director
Jun 3, 2026
AWARD25,146 sh
Jun 3, 2026
Beyer Pat
Director
Jun 3, 2026
AWARD25,146 sh
Jun 3, 2026
Ladone Mary Kay
Director
Jun 3, 2026
AWARD25,146 sh
Jun 3, 2026
HAWKINS WILLIAM A
Director
Jun 3, 2026
AWARD30,994 sh
Jun 3, 2026
Cowdy Philip G.
Director
Jun 3, 2026
AWARD25,146 sh
Jun 3, 2026
STALNECKER SUSAN M
Director
Jun 3, 2026
AWARD25,146 sh
Jun 3, 2026
McMurry-Heath Michelle
Director
Jun 3, 2026
AWARD25,146 sh
Jun 3, 2026
SUTTER MARTIN P
Director
Jun 3, 2026
AWARD25,146 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
3,022,935
shares short
-4.9%
vs prior settlement
6.6
days to cover
≈3.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 13, 2026 SEC
Brown Advisory Inc. disclosed a 5.8% passive stake in Bioventus Inc. via Schedule 13G, reporting 3,960,468 shares of…
SC 13G · Impact 3/10
Nov 6, 2026 SEC
Four institutional investors added to Bioventus positions in Q3 2026, totaling $1.8M in net buying, while three…
INST-CLUSTER · Impact 3/10
Nov 2, 2026 SEC
Bioventus reported Q3 2026 revenue of $142.4M (+3% YoY), slightly below the $149.5M consensus, and non-GAAP EPS of…
8-K · Impact 5/10
Nov 2, 2026 Earnings
Bioventus Reports Third Quarter Financial Results
DURHAM, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Co
Sep 30, 2026 Inst.
AMERICAN CENTURY COMPANIES INC · ADD
2,162,426 shares ($29.5M)
Sep 30, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC · TRIM
432,136 shares ($5.9M)
Jun 3, 2026 Insider
NEELS GUIDO J was granted 25,146 shares
Director
Jun 3, 2026 Insider
Beyer Pat was granted 25,146 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

17 filings · 1 press release · 6 bullish · 2 bearish · 1 mixed · 8 neutral
All BVS filing & press-release reports (18)